Y-Mabs Therapeutics Total Revenue

Y-Mabs Therapeutics's total revenue stands at $85M as of June 2025. That compares with $87M in the prior-year period — down 1.3% year over year. That is below the Healthcare sector average of $110B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Y-Mabs Therapeutics reported $85M in total revenue versus $87M a year earlier — a 1.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Y-Mabs Therapeutics sits lower the Healthcare benchmark ($110B) with a total revenue of $85M. That is roughly 99.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $87M in the prior-year period — down 1.3% year over year. Sustained growth in total revenue can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Y-Mabs Therapeutics's total revenue evolved across reporting periods, while the comparison chart places YMAB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.